Dermatology Update 2016

SESSIONS & ABSTRACTS

Montréal, Le Centre Sheraton - NOVEMBER 3-6, 2016

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis

Presentation available

Download File

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pooled Efficacy Results from the Subgroup of Canadian Patients in Two Phase III Randomized Controlled Trials (ESTEEM 1 and 2)

Dr. Kim A. Papp, MD, PhD

Probity Medical Research, Waterloo, ON, Canada

Speakers

Dr. Kim Papp

Dr. Kim Papp

Dermatologist, Kitchener, Ontario

References